BARAMULLA: Drug Department Friday filed a criminal complaint against 7 accused including three big pharmaceutical companies of India in the court of law after drug laboratory analysis report confirmed that drugs produced and supplied by these companies in Kashmir are not of standard quality and are spurious.
Standing Council for Drug Department Baramulla Advocate Saleem Yousuf told CNS that Drug Inspector Sopore and Baramulla after receiving multiple complaints from attendants and medicos had lifted the samples of three injections namely, Dicoliv, Phenegram B, and Lezone from different medical shops of the district in July 2014. The samples were referred to laboratory and after receiving the negative report about these samples, the Department accordingly filed a criminal complaint under Drug and Cosmetic Act in the court of Principal and District Sessions Judge Baramulla Tauqeer Ahmed.
The criminal complaint was filed against 7 accused and co-accused including three big pharmaceutical companies of India. They are Sayora Laboratories District Solan Himachal Pradesh, Chief Manager Nicholas Piramal India District Dhar Madhya Pradesh, Sushil Goyal proprietor Total Healh Care Himachal Pradesh, Rajeev Kumar Singhal (Haryana) of Total Health Care, Arjun Ram- Drug Analyst Rajhstan, Gousia Medicate Boniyar and Raja Distributors Sopore.
Principal and District Sessions Judge Baramulla Tauqeer Ahmed before transferring the case to the Additional District and Sessions Judge (Special Court) Baramulla issued notices against all the accused and directed them to ensure their presence on the next hearing of the case. The case has been listed for next hearing on 27 February next month. (CNS)
Be Part of Quality Journalism
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast.